Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
馬薩諸塞州劍橋，2024年5月28日（GLOBE NEWSWIRE）——Foghorn Therapeutics Inc.（納斯達克股票代碼：FHTX）是一家臨床階段的生物技術公司，開創了一類通過糾正異常基因表達來治療嚴重疾病的新藥物，今天宣佈管理層將參加傑富瑞全球醫療保健會議和高盛45指數第四 年度全球醫療保健會議。Foghorn最初的重點是腫瘤學，其基因流量控制平台以及由此產生的廣泛管道有可能改變患有各種疾病的人們的生活。
Jefferies Global Healthcare Conference
傑富瑞全球醫療保健會議
- Presentation: Wednesday, June 5, 2024, at 3:30 p.m. ET at the Marriott Marquis New York, New York
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in one-on-one meetings on Wednesday, June 5
- 演講：美國東部時間 2024 年 6 月 5 日星期三下午 3:30 在紐約馬奎斯萬豪酒店舉行
- Foghorn 主持人：總裁兼首席執行官阿德里安·戈特沙爾克
- 請在此處找到網絡直播的鏈接
- 管理層還將參加6月5日星期三的一對一會議
Goldman Sachs 45th Annual Global Healthcare Conference
高盛 45第四 年度全球醫療保健會議
- Presentation: Monday, June 10, 2024, at 3:20 p.m. ET at the Loews Miami Beach Hotel, Miami Beach, Florida
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in one-on-one meetings during the conference
- 演講：美國東部時間 2024 年 6 月 10 日星期一下午 3:20 在佛羅里達州邁阿密海灘洛伊斯邁阿密海灘酒店舉行
- Foghorn 主持人：總裁兼首席執行官阿德里安·戈特沙爾克
- 請在此處找到網絡直播的鏈接
- 管理層還將在會議期間參加一對一的會議
A webcast of both presentations can be accessed under "Events & Presentations" in the Investors section of the Company's website, , and will be available for 30 days.
兩場演講的網絡直播均可在公司網站 “投資者” 部分的 “活動與演講” 下觀看，並將持續30天。
About Foghorn Therapeutics
Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at for more information about the Company, and follow us on X (formerly Twitter) and LinkedIn.
關於Foghorn Therapeutics
Foghorn Therapeutics正在發現和開發一類針對染色質監管系統中基因決定的依賴關係的新型藥物。通過其專有的可擴展基因流量控制平台，Foghorn正在系統地研究、識別和驗證染色質監管系統中的潛在藥物靶標。該公司正在開發多種腫瘤學候選產品。訪問我們的網站，了解有關公司的更多信息，並在 X（前身爲 Twitter）和 LinkedIn 上關注我們。
Contacts:
聯繫人：
Greg Dearborn, Foghorn Therapeutics Inc. (Investors)
gdearborn@foghorntx.com
Greg Dearborn，Foghorn Therapeutics Inc.（投資者）
gdearborn@foghorntx.com
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
khellsvik@foghorntx.com
Karin Hellsvik，Foghorn Therapeutics Inc.（投資者與媒體）
khellsvik@foghorntx.com
Adam Silverstein, ScientPR (Media)
adam@scientpr.com
亞當·西爾弗斯坦，ScientPR（媒體）
adam@scientpr.com